GlassScriptPhysician profile
Davida N Gerena
NPI 1538325113
$9,115.37
in general payments reported to CMS, 2019-2025
19 companies · $8,601 in 2025
The $8,601 reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.54 · 2020: $70.87 · 2021: $73.10 · 2022: $69.70 · 2023: $81.77 · 2024: $165 · 2025: $8,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,525 · Travel and Lodging: $1,415 · Food and Beverage: $882 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,525.00 |
| Travel and Lodging | $1,415.39 |
| Food and Beverage | $881.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $8,380.93 | 2025 | |
| Indivior INC. | $205.06 | 2022-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $75.16 | 2020-2025 | Vaxelis, Vaxneuvance, Rotateq |
| Xeris Pharmaceuticals, INC. | $65.71 | 2024-2025 | Recorlev |
| Cranial Technologies, INC | $51.09 | 2019-2023 | Doc Band |
| Sanofi-Aventis U.S. LLC | $43.78 | 2025 | |
| Abbott Laboratories | $41.69 | 2020-2021 | |
| Mannkind Corporation | $36.17 | 2022-2023 | Afrezza |
| Biohaven Pharmaceuticals, INC. | $34.03 | 2021 | |
| Braeburn INC. | $33.26 | 2024-2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.18 | 2019 | |
| Gilead Sciences, INC. | $19.42 | 2020 | |
| Glaxosmithkline, LLC. | $17.35 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.83 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.39 | 2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $14.59 | 2023 | Inpefa |
| Athena Bioscience, LLC | $11.50 | 2023 | Nexiclon Xr |
| Genentech USA, INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davida Gerena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.